The long-planned debut of Aralez Pharmaceuticals Inc., a Toronto-based company conceived by specialty pharma veteran Adrian Adams as a profitable and tax-advantaged combination of Pozen Inc. and Tribute Pharmaceuticals Canada Inc., moved closer to finality this week with the successful registration of Aralez shares on Nasdaq and the ironing out of an aspirin supply issue that has weighed on the company since 2014.